Biocare to Distribute Invitrogen's HER2 Test Kit- Breast Cancer

One of the first kits on the market, as the article states the test can assess whether breast cancer patients would benefit from Genentech's Herceptin cancer drug. The website as of today asks that you contact a sales person for additional information. BD

The test, which received US Food and Drug Administration clearance in early July, can be used to assess whether breast cancer patients should be treated with Genentechs Herceptin (trastuzumab). It marked the first pre-market approval Invitrogen has received from FDA for a diagnostic product. Biocare is a supplier of immunohistochemistry reagents, multiplex stains, and automated platforms for the anatomic pathology market. Laboratories purchasing Invitrogens HER2 test kit must complete Invitrogens HER2 CISH certification program, as required by the FDA clearance. The firm expects the primary users to be pathologists, oncologists, and histotechnologists who determine the best course of treatment for breast cancer patients.